Overexpression of SLC7A11 has been reported in various cancers, including lung, breast, and ovarian cancers, where it contributes to tumor growth, chemoresistance, and poor prognosis (Liu et al., 2020). This evidence concerns the gene SLC7A11 and neoplasm.